Related Experiment Videos

Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency

Simon J Davidson1, Natalie Turner, Louise Tillyer

  • 1Department of Haematology, Royal Brompton Hospital, London, UK. s.davidson@rbht.nhs.uk

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|October 2, 2010
PubMed

Insights

Patients with factor VII deficiency require careful warfarin dosing. Monitoring baseline prothrombin time and factor VII levels allows for safe anticoagulation in these individuals.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy and atrial fibrillation necessitate anticoagulation.
  • Warfarin is a common oral anticoagulant used to prevent thromboembolic events.

Observation:

  • A 50-year-old male experienced over-anticoagulation with standard warfarin induction doses.
  • Baseline prothrombin time was prolonged, revealing a mild factor VII deficiency.
  • Molecular analysis identified two mutations in the factor VII gene.

Findings:

  • Low-dose warfarin therapy successfully stabilized the patient with a target International Normalized Ratio (INR) of 3.0.
  • Factor VII levels and thrombin generation studies informed dosage adjustments and therapeutic range.
  • Anticoagulation was well-tolerated despite the congenital factor VII deficiency.

Implications:

  • Baseline prothrombin time assessment is crucial before initiating oral anticoagulation.
  • Personalized warfarin dosing strategies are essential for patients with factor VII deficiency.
  • Effective anticoagulation management is achievable in patients with rare coagulation disorders.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...